Fluoxetine once every third day in the treatment of major depressive disorder
✍ Scribed by Ümit Tural; Emin Önder
- Publisher
- Springer-Verlag
- Year
- 2003
- Tongue
- English
- Weight
- 270 KB
- Volume
- 253
- Category
- Article
- ISSN
- 1433-8491
No coin nor oath required. For personal study only.
📜 SIMILAR VOLUMES
## Abstract Eighty‐three patients were recruited in a multicentre study concerning the usefulness of benzodiazepines (BZ) in major depressive disorders, diagnosed according to the DSM‐III‐R criteria. After 1 week wash‐out, patients were randomized to clomipramine (CLMP) or CLMP plus bentazepam (BTZ
This study evaluated the clinical efficacy and safety of a new triazolobenzodiazepine, adinazolam, and imipramine in 40 patients with carefully diagnosed major depressive disorder. Overall, adinazolam was found to be as effective as imipramine. In addition, when patients with more severe, melancholi
Depression is treated by a great variety of antidepressant treatments. SSRIs (such as fluoxetine) are well known: it is, however, sure that further progress is needed and the search for antidepressants with other mechanisms of action (such as tianeptine) or different efficacy is still of interest. A
Eight patients suering from major depression were treated with trazodone 150 or 200 mg bid (non-responders) over 5 weeks, preceded and followed by a placebo week. Cognitive functioning was tested in the morning at the end of each treatment week. Before trazodone treatment commenced, patients' cognit